ChemicalBook--->CAS DataBase List--->28395-03-1

28395-03-1

28395-03-1 Structure

28395-03-1 Structure
IdentificationMore
[Name]

Bumetanide
[CAS]

28395-03-1
[Synonyms]

3-(AMINOSULFONYL)-5-(BUTYLAMINO)-4-PHENOXYBENZOIC ACID
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
BUMETANIDE
bumex
burinex
RO 10-6338
3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-benzoicaci
3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoicaci
3-Butyuamino-4-phenoxy-5-sutfamoylbenzoicacid
burine
fontego
fordiuran
lunetoron
pf1593
segurex
Bumetanide (FDA)
BumetanideUSP
Bufenox
Lixil
3-n-Butylamino-4-phenoxy-5-sulfamoylbenzoic acid
[EINECS(EC#)]

249-004-6
[Molecular Formula]

C17H20N2O5S
[MDL Number]

MFCD00078949
[Molecular Weight]

364.42
[MOL File]

28395-03-1.mol
Chemical PropertiesBack Directory
[Appearance]

Crystalline Solid
[Melting point ]

230-2310C
[Boiling point ]

571.2±60.0 °C(Predicted)
[density ]

1.2812 (rough estimate)
[refractive index ]

1.6510 (estimate)
[storage temp. ]

2-8°C
[solubility ]

Practically insoluble in water, soluble in acetone and in alcohol, slightly soluble in methylene chloride. It dissolves in dilute solutions of alkali hydroxides.
[form ]

neat
[pka]

pK1 3.6, pK2 7.7(at 25℃)
[color ]

White to Light Yellow
[Water Solubility ]

Soluble in ethanol (10 mg/ml), DMSO (25 mg/ml), acetone, benzene, methanol, propylene glycol, and water (<1 mg/ml).
[Usage]

Diuretic
[CAS DataBase Reference]

28395-03-1(CAS DataBase Reference)
[EPA Substance Registry System]

Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy- (28395-03-1)
Safety DataBack Directory
[WGK Germany ]

3
[RTECS ]

DG4910000
[HS Code ]

2935904000
[Toxicity]

LD50 i.v. in mice: 330 mg/kg (Oestergaard)
Raw materials And Preparation ProductsBack Directory
[Raw materials]

Ammonium hydroxide-->Sodium borohydride-->Phenol-->Sodium bisulfite-->Chlorosulfonic acid-->Benzenesulfonamide-->4-Chlorobenzoic acid-->Butyl formate-->m-Carboxybenzenesulfonyl chloride-->1-Butanol-->Hydrogen-->Sodium bicarbonate-->Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-, methyl ester-->butyl 3-aminosulphonyl-5-butylamino-4-phenoxybenzoate-->3-amino-5-(aminosulphonyl)-4-phenoxybenzoic acid
[Preparation Products]

sodium 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoate
Material Safety Data Sheet(MSDS)Back Directory
[msds information]

3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid(28395-03-1).msds
Hazard InformationBack Directory
[Chemical Properties]

Crystalline Solid
[Originator]

Burinex,Leo,UK,1973
[Uses]

antineoplastic, alkylating agent
[Uses]

Bumetanide is a diuretic.
[Uses]

Bumetanide is used for relieving edema associated with cardiac insufficiency, for liver and kidney diseases including nephrotic syndrome, for ascites, and hypertension.
[Definition]

ChEBI: A member of the class of benzoic acids that is 4-phenoxybenzoic acid in which the hydrogens ortho to the phenoxy group are substituted by butylamino and sulfamoyl groups. Bumetanide is a diuretic, and is used for treatment of oedema associated with congestive heart failure, hepatic and renal disease.
[Manufacturing Process]

Preparation of 3-Nitro-4-Phenoxy-5-Sulfamylbenzoic Acid: A mixture of 4- chloro-3-nitro-5-sulfamylbenzoic acid (140 grams), phenol (100 grams), sodium hydrogencarbonate (170 grams), and water (1.000 ml) was heated to 85°C while stirring and kept at this temperature for 16 hours. After cooling to 4°C, the precipitated sodium salt of 3-nitro-4-phenoxy-5-sulfamylbenzoic acid was filtered off and washed with ice water. The sodium salt was dissolved in boiling water (3,000 ml), and the 3-nitro-4-phenoxy-5-sulfamylbenzoic acid was precipitated by addition of 4N hydrochloric acid. After cooling, the acid was isolated by suction and dried. The melting point was 255°-256°C.
Preparation of 3-Amino-4-Phenoxy-5-Sulfamylbenzoic Acid: A suspension of 3- nitro-4-phenoxy-5-sulfamylbenzoic acid (20 grams) in water (100 ml) was adjusted to pH 8 by addition of 1N lithium hydroxide. The resulting solution was hydrogenated at room temperature and 1.1 atmospheres hydrogen pressure after addition of Pd on carbon catalyst (0.6 grams catalyst containing 10% Pd). After the hydrogen uptake had become negligible, the catalyst was removed by filtration, and the 3-amino-4-phenoxy-5-sulfamylbenzoic acid was precipitated from the filtrate by addition of 4N hydrochloric acid to pH 2.5. After recrystallization from aqueous ethanol and drying, the melting point was 255°-256°C.
Preparation of 3-n-Butylamino-4-Phenoxy-5-Sulfamylbenzoic Acid: To a suspension of 3-amino-4-phenoxy-5-sulfamyibenzoic acid (10 grams) in nbutanol (200 ml), concentrated sulfuric acid (2 ml) was added while stirring. The reaction mixture was heated under reflux under conditions in which the water formed during the reaction could be removed. When, after dilution with n-butanol, the NMR-spectrum of a sample of the reaction mixture showed at the two doublets of the aromatic protons in ring A that the butyl-3-amino-4- phenoxy-5-sulfamylbenzoate formed as an intermediate was more than 90% converted to the corresponding 3-n-butylaminobenzoate, 2 N sodium hydroxide (200 ml) was added and the boiling was continued for 45 minutes. After the saponification, the reaction mixture was neutralized to pH 8 by addition of concentrated hydrochloric acid.
By cooling, the sodium salt of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid precipitated. It was filtered off and recrystallized from water (100 ml). The sodium salt, crystallizing with 3 molecules of water, was then dissolved in boiling water (200 ml), 1N hydrochloric acid was added to pH 2.5, and after cooling the precipitated 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid was collected by filtration. After recrystallization from aqueous ethanol and drying, the pure compounds were obtained with melting point 230°-231°C.
[Brand name]

Bumex (Roche).
[Therapeutic Function]

Diuretic
[Biological Activity]

Loop diuretic that inhibits the Na + /2Cl - /K + (NKCC) cotransporter. More potent than furosemide (5-(Aminosulfonyl)-4-chloro-2-([2-furanylmethyl]amino)benzoic acid ).
[Biochem/physiol Actions]

Inhibitor of Na+/K+/Cl- cotransporter.
[Clinical Use]

A diuretic structurally related to furosemide is bumetanide. This compound also functions as a high-ceiling diuretic in the ascending limb of the loop of Henle. It has a duration of action of approximately 4 hours. The uses of this compound are similar to those described for furosemide. The dose of bumetanide is 0.5 to 2 mg/day given as a single dose.
[Synthesis]

Bumetanide, 3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid (21.4.6), is synthesized from 4-chlorobenzoic acid. In the first stage of synthesis, it undergoes sulfonylchlorination by chlorosulfonic acid, forming 4-chloro-3-chlorosulfonylbenzoic acid (21.4.1), which is further nitrated with nitric acid to 4-chloro-3-chlorosulfonyl-5-nitrobenzoic acid (21.4.2). Reacting this with ammonia gives 5-aminosulfonyl-4-chloro-3-nitrobenzoic acid (21.4.3), which when reacted with sodium phenolate is transformed into 5-amino-sulfonyl-3-nitro-5-phenoxybenzoid acid (21.4.4). Reduction of the nitro group in this product by hydrogen using a palladium on carbon catalyst gives 3-amino-5-aminosulfonyl- 5-phenoxybenzoic acid (21.4.5). Finally, reacting this with butyl alcohol in the presence of sulfuric acid gives the desired bumetanide (21.4.6).

Synthesis_28395-03-1

[Drug interactions]

Potentially hazardous interactions with other drugs
Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect with NSAIDs.
Anti-arrhythmics: risk of cardiac toxicity with anti-arrhythmics if hypokalaemia occurs; effects of lidocaine and mexiletine antagonised.
Antibacterials: increased risk of ototoxicity with aminoglycosides, polymyxins and vancomycin; avoid with lymecycline.
Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
Antiepileptics: increased risk of hyponatraemia with carbamazepine.
Antifungals: increased risk of hypokalaemia with amphotericin.
Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect with alpha-blockers; increased risk of ventricular arrhythmias with sotalol if hypokalaemia occurs.
Antipsychotics: increased risk of ventricular arrhythmias with amisulpride or pimozide if hypokalaemia occurs - avoid with pimozide; enhanced hypotensive effect with phenothiazines.
Atomoxetine: increased risk of ventricular arrhythmias if hypokalaemia occurs.
Cardiac glycosides: increased toxicity if hypokalaemia occurs.
Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
Lithium: risk of toxicity.
[Metabolism]

About 80% of a dose of bumetanide is excreted in the urine, about 50% as unchanged drug, and 10-20% in the faeces. No active metabolites are known. In patients with chronic renal failure the liver takes more importance as an excretory pathway although the duration of action is not markedly prolonged.
[storage]

Store at RT
Spectrum DetailBack Directory
[Spectrum Detail]

Bumetanide(28395-03-1)1HNMR
Well-known Reagent Company Product InformationBack Directory
[Sigma Aldrich]

28395-03-1(sigmaaldrich)
28395-03-1 suppliers list
Company Name: Hebei Mojin Biotechnology Co., Ltd
Tel: +8613288715578 , +8613288715578
Website: www.mojinchemical.com
Company Name: Wuhan Han Sheng New Material Technology Co.,Ltd
Tel: +8617798174412 , +8617798174412
Website: www.hsnm.com.cn/
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd
Tel: 010-60279497
Website: http://www.cooperate-pharm.com
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: +86-0371-55170693 +86-19937530512 , +86-19937530512
Website: https://www.tianfuchem.com/
Company Name: career henan chemical co
Tel: +86-0371-86658258
Website: https://www.coreychem.com/
Company Name: Hebei Guanlang Biotechnology Co., Ltd.
Tel: +86-19930503282 , +86-19930503282
Website: https://www.chemicalbook.com/manufacturer/crovell/
Company Name: Chongqing Chemdad Co., Ltd
Tel: +86-023-61398051 +8613650506873 , +8613650506873
Website: http://www.chemdad.com/
Company Name: Alchem Pharmtech,Inc.
Tel: 8485655694
Website: www.chemicalbook.com/ShowSupplierProductsList454175/0.htm
Company Name: Hebei shuoxi biotechnology co. LTD
Tel: +8613081092107
Website: www.chemicalbook.com/ShowSupplierProductsList1203517/0.htm
Company Name: CONIER CHEM AND PHARMA LIMITED
Tel: +8618523575427 , +8618523575427
Website: http://www.conier.com/
Company Name: Antai Fine Chemical Technology Co.,Limited
Tel: 18503026267 , 18503026267
Website: www.chemicalbook.com/ShowSupplierProductsList1980510/0.htm
Company Name: WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD
Tel: +8615377521700 , +8615377521700
Website: https://www.chemicalbook.com/manufacturer/wuhan-circle-powder-technology-306/
Company Name: WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD
Tel: 027-81302090 15327141851 , 15327141851
Website: http://www.wuhandky.com
Company Name: Hubei Ipure Biology Co., Ltd
Tel: +8613367258412 , +8613367258412
Website: www.ipurechemical.com
Company Name: Hefei TNJ Chemical Industry Co.,Ltd.
Tel: 0551-65418671
Website: https://www.tnjchem.com
Company Name: Shanghai Rochi Pharmaceutical Co.,Ltd.
Tel: 21-38751876 +8615000076078 , +8615000076078
Website: http://www.rochipharma.com/en/index.aspx
Company Name: ANHUI WITOP BIOTECH CO., LTD
Tel: +8615255079626 , +8615255079626
Website: www.chemicalbook.com/showsupplierproductslist418627/0_en.htm
Company Name: Xi'an MC Biotech, Co., Ltd.
Tel: 029-89275612 +8618991951683 , +8618991951683
Website: www.chemicalbook.com/ShowSupplierProductsList1759320/0.htm
Tags:28395-03-1 Related Product Information
99-05-8 2438-72-4 100-09-4 150-13-0 65-85-0 619-84-1 50-50-0 64-77-7 23184-66-9 80060-09-9 153012-65-8 1216739-35-3 67-36-7 55837-27-9 1571-72-8 118-92-3 104-51-8 109-73-9